Indication
Myeloid Neoplasm
10 clinical trials
17 products
6 drugs
Clinical trial
A Phase I/II Study of Azacitidine, Venetoclax and Pevonedistat in Adults With Newly Diagnosed Secondary or Therapy-Related AMLStatus: Active (not recruiting), Estimated PCD: 2025-01-31
Product
AzacitidineProduct
PevonedistatProduct
VenetoclaxClinical trial
PD-1 Inhibition With Nivolumab for the Treatment of Patients With Acute Myeloid Leukemia in Remission at High Risk for RelapseStatus: Completed, Estimated PCD: 2023-08-08
Product
NivolumabClinical trial
Dose-Finding (Phase 1) Study of Continuous Infusion Cladribine, Cytarabine and Mitoxantrone (CI-CLAM) for Adults With Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms Treated at UW/SCCAStatus: Terminated, Estimated PCD: 2021-10-13
Product
CladribineProduct
CytarabineProduct
MitoxantroneClinical trial
A Phase 1 Single-Center Trial Combining Venetoclax With G-CSF, Cladribine, Cytarabine, and Mitoxantrone (CLAG-M) for Patients With AML and High-Grade Myeloid NeoplasmsStatus: , Estimated PCD: 2024-12-31
Clinical trial
A Prospective, Multicenter, Single-Arm Pilot Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid NeoplasmsStatus: Recruiting, Estimated PCD: 2025-08-01
Drug
CPX-351Product
MHAClinical trial
Randomized Phase 2 Trial of CPX-351 (Vyxeos) vs. CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less-Fit Adults With Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid NeoplasmStatus: Recruiting, Estimated PCD: 2025-05-31
Clinical trial
A Randomized Trial for Patients With High-Grade Myeloid Neoplasms With Measurable Residual Disease (MRD): CPX-351 vs. Immediate Allogeneic Hematopoietic Cell TransplantationStatus: Terminated, Estimated PCD: 2023-08-27
Clinical trial
A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITDStatus: Active (not recruiting), Estimated PCD: 2019-03-31
Product
AsparaginaseProduct
BortezomibProduct
DaunorubicinProduct
EtoposideProduct
SorafenibClinical trial
A 2 Step Approach to Haploidentical Transplant Using Radiation-Based Reduced Intensity ConditioningStatus: Recruiting, Estimated PCD: 2024-10-01
Product
Mycophenolate MofetilDrug
VarlilumabDrug
cyclophosphamideDrug
fludarabineDrug
MelphalanClinical trial
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid MalignanciesStatus: Recruiting, Estimated PCD: 2026-09-01
Product
DecitabineDrug
Filgrastim